Colorectal cancer (CRC) has a high prevalence both globally and in Indonesia, with projections of increasing cases as the prevalence of type 2 diabetes mellitus (T2DM) rises. The complex relationship between CRC and T2DM, including increased risk and complications from chemotherapy, has driven study into the potential of metformin as an anticancer agent, although the existing findings remain varied. This evidence-based case report (EBCR) aimsed to evaluate the role of metformin as a prognostic factor for the survival of CRC patients with T2DM. The journal search was conducted using four databases: PubMed, EBSCOhost, Scopus, and manual searching. By setting inclusion and exclusion criteria, followed by screening of titles and abstracts, 10 studies were included for review in the preparation of this EBCR. The ten studies reviewed are valid prognostic meta-analyses, showing that the use of metformin significantly improves survival in CRC patients with T2DM, with a hazard ratio (HR) ranging from 0.60 to 0.82, and better outcomes observed in the Asian population. Most of the studies also demonstrate clinically significant results in cancer-specific survival, although two studies were not statistically significant. The patient characteristics in these studies are similar to the patient of the case illustration, making the results of this EBCR applicable to these patients. Recent evidence shows that metformin can reduce the risk of death in CRC patients with T2DM, particularly in the early stages and with normal kidney and liver function. However, further studies are needed to confirm its effectiveness and safety before it can be widely recommended.